NEW YORK, April 16, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Global Genetic Testing Industry
http://www.reportlinker.com/p098275/Global-Genetic-Testing-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_
This report analyzes the worldwide markets for Genetic Testing in US$ Million. The US market is analyzed by the following Segments: Prenatal and Newborn Genetic Testing, Pharmacogenomic Testing, and Predictive testing. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets. The report profiles 76 Companies including many key and niche players such as Abbott Laboratories, Abbott Molecular, Inc., Applied Biosystems Inc., AutoGenomics, Inc., BioRad Laboratories, Celera Group, ELITech Group, PerkinElmer, Inc., Quest Diagnostics, Inc., Roche Diagnostics Corp., Roche Molecular Diagnostics, Inc., and Transgenomic, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-2
Quantitative Techniques & Analytics I-3
Product Definitions and Scope of Study I-3
Prenatal Diagnosis I-3
Newborn Screening I-4
Pharmacogenetics/Pharmacogenomics I-4
Predictive Testing I-4
II. EXECUTIVE SUMMARY
1. OVERVIEW II-1
Progressing from Service Driven to Product-Driven Market II-1
Genetic Testing: The Rapidly Growing Segment of Molecular
Diagnostics Market II-1
Table 1: Worldwide In-Vitro Diagnostics Market by Segment
(2008) - Percentage Breakdown of Value Sales for
Immunochemistry, Diabetes, Clinical Chemistry, Point-of-Care
Testing, Molecular Diagnostics, Hematology, Coagulation, and
Others (includes corresponding Graph/Chart) II-1
Table 2: World In-Vitro Diagnostic (IVD) Market by Leading
Players (2008): Market Share Breakdown for Roche, Siemens,
Abbott Diagnostics, Becton Dickinson, Beckman Coulter, OCD ,
BioMerieux, Sysmex, and Others (includes corresponding
Graph/Chart) II-2
Table 3: World Molecular Diagnostics Market (2007-2015): Key
Segments [Oncology, Genetic Testing, Blood Screening, and
Infectious Disease Testing] Ranked by Growth (includes
corresponding Graph/Chart) II-2
Genetic Testing Outlook Brightens II-3
Issues & Trends Affecting the Market II-3
Challenges Faced II-3
Genetic Counseling: Gaining Momentum II-4
Online Approach Gains Momentum II-4
Pediatric Genetic Testing for Screening Adult Onset Disorders
Fast Gaining Acceptance II-4
Recommendations of ACOG and ACGM Augments Demand for CF Testing II-4
Ethical Issues & Need for Appropriate Regulating Policies II-5
Routine Clinical Testing Vs. Predictive Genetic Testing II-5
Issues Related to Genetic Tests for Obesity II-6
Diagnosis and Treatment during Pregnancy, an Effective Way of
Alleviating Syphilis Related Deaths and Stillbirths II-6
Competition II-7
Table 4: Leading Players in the Worldwide Genetic Testing
Market (2006): Percentage Breakdown by Value Sales for Roche
Diagnostics / Affymetrix, Abbott Laboratories, Bio-Rad
Laboratories, and Others (includes corresponding Graph/Chart) II-7
2. PRODUCT OVERVIEW II-8
Preface to Genetic Testing II-8
Genetic Testing and its Applications II-8
Gene Candidate and Genome Screen II-9
'DNA Chip' to Chip into Genetic Field II-9
Techniques Used to Identify Changes in Genes II-10
Types of Genetic Testing II-10
Steps in Genetic Testing Process II-12
Limitations II-12
Risks and Other Limitations of Genetic Testing II-13
Medical Institutions to Reap the Benefit of Genetic Testing II-13
Pharmacogenetics/Pharmacogenomics II-13
Review of Select Genetic Tests II-13
Cystic Fibrosis II-13
Breast and Ovarian Cancer II-13
Alzheimer's Disease II-14
Colorectal Cancer II-14
Haemochromatosis (HH) II-14
Cowden Syndrome II-14
Huntington's Disease II-14
Costs of Select Tests II-15
Table 5: Costs of Select Genetic Tests II-15
3. PRODUCT LAUNCHES II-16
Health Diagnostic Laboratory Introduces CYP2C19 Genetic Test II-16
Response Genetics Introduces EML4-ALK Genetic Test II-16
Roche Launches GS Junior System II-16
Acton Biotech Introduces Genetic Test for Warfarin II-16
Ambry Genetics Launches AmbryScreen II-17
Family Tree DNA Introduces Family Finder DNA Test II-17
Machaon Unveils Clinical Testing Service for Warfarin-
Prescribed Patients II-17
Helicos BioSciences Develops MDx Tests II-17
AccessDNA Launches Telephone Based Genetic Counseling Services II-18
DNA Genotek Unveils Performagene™ LIVESTOCK II-18
Equinome Introduces Speed Gene Test II-18
Applied Biosystems Unveils 3500 Series and 3500 DX Series
Genetic Analyzer II-19
Luminex Introduced New Range of Cystic Fibrosis Tests II-19
Ambry Genetics Launches Whole-Genome Chromosomal Microarray
Analysis II-20
Myriad Genetics Introduces OnDose for Cancer Diagnosis II-20
Xenomics to Introduce Innovative Gender Prediction Test II-20
ParagonDx Offers Genetic Testing II-21
Interleukin Genetics Unveils Bone Health Genetic Test II-21
TessArae® Launches Human Genetic Disease Testing Solutions II-21
IBM to Develop Nanoscale DNA Sequencer II-21
Response Genetics Unveils ResponseDX: Gastric™ Genetic Test Panel II-22
Axial Biotech Rolls out SCOLISCORE™ AIS Prognostic Test II-22
CyGene Laboratories Launches Predictive Genetic Products in
Russia II-22
Cepheid Releases Xpert® BCR-ABL Monitor Test II-22
Interleukin Genetics Introduces Inherent Health™ Brand of
Genetic Tests II-22
PGxHealth Introduces FAMILION® DCM Test II-23
Correlagen Diagnostics Launches CardioGeneScan Test II-23
PsoriasisDX Introduces Genetic Test for Psoriatic Arthritis II-23
4. PRODUCT INTRODUCTIONS/INNOVATIONS - A HISTORIC PERSPECTIVE BUILDER II-24
Clinical Data Introduces Genetic Test for HCM II-24
Iverson Genetic Diagnostics Unveils Warfarin Sensitivity Tests II-24
HairDX Unveils New Test for Predicting Female Hair Loss II-24
HairDX Introduces Genetic Test for Male Baldness II-25
Clinical Data Introduces Pharmacogenetic Test for Clozapine II-25
Seegene Launches 18-Plex Genotyping Test II-25
InterGenetics Introduces Onco Vue II-26
Applied Biosystems Introduces Novel DNA Technologies II-26
Dabur Introduces CML Quest II-26
deCODE Launches deCODE T2 II-26
DNAPrint Announces the Launch of Ancestry Indicator II-27
Genzyme Unveils New Mutation Analysis Test II-27
Orchid BioSciences Introduces New Testing Kit II-27
Focus Diagnostics Introduces GenomEx(TM) Service II-27
Relative Genetics Introduces Y-chromosome haplogroup Service
on Web Site II-28
Genzyme Unveils Upgraded CFplus Cystic Fibrosis (CF) Mutation
Analysis II-28
5. RECENT INDUSTRY ACTIVITY II-29
LabCorp Acquires Orchid Cellmark II-29
Quest Diagnostics Snaps Up Celera II-29
Transgenomic Snaps Up Diagnostics Arm of Clinical Data II-29
Transgenomic Licenses Intellectual Property from Integragen II-29
Signal Genetics Collaborates with Array BioPharma II-30
Genzyme Divests Genetic Testing Business II-30
Fujirebio to Take over Innogenetics II-30
Response Genetics Inks License Agreement with GSK II-30
Response Genetics and Genetic Technologies Sign Distribution Pact II-31
Thermo Fisher Scientific Inks Agreement to Acquire Finnzymes II-31
Fluidigm Enters into Partnership with IntegraGen II-31
Genetic Technologies Takes Over Assets of Perlegen Sciences II-31
Orchid Cellmark Acquires Paternity and Immigration DNA Testing
Business Division of Strand Analytical Laboratories II-32
Al Borg Laboratories Acquires Majority Stake in Medical
Genetics Center II-32
BioReference Laboratories Takes Over Lenetix Medical Screening
Laboratory II-32
PerkinElmer to Acquire Signature Genomic Laboratories II-33
Xenomics Changes Name to TrovaGene II-33
BioServe Signs Agreement with NGC Medical II-33
Roche Signs Agreement with IBM II-33
DermaGenoma Merges with Developer of Dermatology Genetic Tests II-33
USDA Purchases Fluidigm EP1 System II-34
The Elitech Group Acquires Nanogen Assets II-34
XDx and Bristol-Myers Squibb Company Signs Collaborative
Agreement II-34
Commonwealth Biotechnologies Divests Assets of Bioanalytical
and Genetic Testing Business II-35
QIAGEN Takes Over DxS II-35
Perkinelmer Takes Over Genetic Screening Business of Surendra
Genetic Labs II-35
Interleukin Genetics Inks Licensing Agreement with LABEC Pharma II-36
deCODE Genetics Inks Licensing Agreements with Celera II-36
Gen-Probe Life Sciences Acquires Tepnel Life Sciences II-36
ARCA Biopharma Merges with Nuvelo II-36
Berkeley HeartLab Enters into Partnership with GenVault II-37
CVS Collaborates with Generation Health to Expand PGx Testing II-37
Oman LNG and Omani Health Ministry Ink Agreements II-37
Aurora and Celera Ink Agreement to Integrate Genetic Testing II-37
Interleukin Genetics Sells Assets of Alcan James Group II-38
PharmaGenoma Launches HairDX Europe II-38
SeqWright Collaborates with PharmaGenoma II-38
PGxHealth Signs Contract with BCBSA II-38
Sequenom Takes Over SensiGen II-39
SCMM and PDI Sign Agreement for Sales Infrastructure II-39
Interleukin Receives Approval for Sale of PST® Test in New York II-39
Interleukin Receives Approval for Sale of PST® Test in New York II-39
Medison Inks Agreement for Exclusive Representation of
GeneXpert in Israel II-40
Surelab and Ambica Launch Genetic Testing in Davao City II-40
Correlagen Diagnostics Acquires Helicos® Genetic Analysis System II-40
Quest to Carry out Genetic Tests on Patients at Scripps Health II-40
6. STRATEGIC CORPORATE DEVELOPMENTS - A HISTORIC PERSPECTIVE BUILDER II-41
Biotage Sells Biosystems Division to QIAGEN II-41
Pfizer Animal Health to Take Over Bovigen and Catapult Genetics II-41
DNA Testing Systems Inks Agreement with DNAPrint Genomics II-41
PerkinElmer Acquires Newborn Metabolic Screening Assets of
Pediatrix II-42
Hologic Acquires Third Wave II-42
Dako Denmark Receives FDA Approval for TOP2A FISH pharmDx Device II-42
Abbott Partners with Roche, OSI and Genentech II-42
Lab21 Partners with Amgen II-43
Medical Solutions Acquires Autogen Bioclear II-43
Nanobac to Acquire DNAPrint Genomics II-44
HairDX and Bosley Join Hands for Offering Genetic Test for
Baldness II-44
Nioxin Inks Agreement with HairDX II-44
Orchid Cellmark Acquires ReliaGene Technologies II-45
Celera Takes Over Atria Genetics II-45
Roche Acquires 454 Life Sciences II-45
BioServe and DNAPrint Genomics Form Strategic Alliance II-45
Gentris Divests Stake in Genetic Testing Unit II-46
LabCorp Announces Genetic Test Partnership for Bucindolol
Prescription II-46
Newsham Genetics Takes Over Monsanto Choice Genetics II-46
BioServe Takes Over Genomics Collaborative II-47
CytoDyn Completes Acquisition of Advanced Genetic Technologies II-47
Sorenson Genomics Takes Over Identigene II-47
Clinical Data Enters into a License Agreement with VCGS II-47
Clinical Data Collaborates with George Washington University II-48
Luminex Takes Over TM Bioscience II-48
Schering-Plough Enters into a Contract with Warnex II-48
Cepheid Acquires Sangtec II-49
Medco Collaborates with Mayo II-49
Lab21 to Offer CLDA's Genetic Test for Cardiac Channelopathy II-49
Clinical Data Pockets Epidauros Biotechnologie II-49
Beijing Adinovo Gene and GENDIA Ink Genetic Test Exchange
Agreement II-50
Genetic Technologies Forms Alliance with UTEK II-50
QIAGEN Acquires Digene II-50
Luminex Inks Development Licensing Agreement with Mayo Clinic II-51
7. TECHNOLOGICAL DEVELOPMENTS - A HISTORIC PERSPECTIVE BUILDER II-52
New Molecular Diagnostic device to Improve Genetic Tests for
Alzheimer disease II-52
Deakin Clinic Offers PGD, a Sophisticated Testing for Genetic
Disorders II-52
New Gene Mapping Method to Enhance Identification of Haplotype
Block II-52
New Non-Invasive test a Better Indicator of Malignancy than
the PSA Test II-52
8. FOCUS ON SELECT GLOBAL PLAYERS II-53
Abbott Laboratories (USA) II-53
Abbott Molecular, Inc. (USA) II-53
Applied Biosystems Inc. (USA) II-53
AutoGenomics, Inc. (USA) II-54
BioRad Laboratories (USA) II-54
Celera Group (USA) II-54
ELITech Group (France) II-54
PerkinElmer, Inc. (USA) II-55
Quest Diagnostics, Inc. (USA) II-55
Roche Diagnostics Corp. (Switzerland) II-56
Roche Molecular Diagnostics, Inc. (USA) II-56
Transgenomic, Inc. (US) II-56
9. GLOBAL MARKET PERSPECTIVE II-58
Table 6: World Recent Past, Current & Future Market Analysis
for Genetic Testing by Geographic Region - US, Canada, Japan,
Europe and Rest of World Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2009 through 2017
(includes corresponding Graph/Chart) II-58
Table 7: World Historic Review for Genetic Testing by
Geographic Region - US, Canada, Japan, Europe and Rest of
World Independently Analyzed with Annual Sales Figures in US$
Million for Years 2003 through 2008 (includes corresponding
Graph/Chart) II-59
Table 8: World 15-Year Perspective for Genetic Testing by
Geographic Region - Percentage Breakdown of Dollar Sales for
US, Canada, Japan, Europe and Rest of World Markets for Years
2003, 2011 & 2017 (includes corresponding Graph/Chart) II-60
III. MARKET
1. THE UNITED STATES III-1
A.Market Analysis III-1
Newborn Testing Gains Ground III-1
Predictive Screening: Another Growth Area III-1
Growth Prospects Aplenty in Preimplantation Genetic Diagnosis III-1
Direct-to-Consumer Testing - A Growing Market III-2
US Regulatory Environment III-2
Genetic Testing Set for Big Boost with New Legislation III-3
DNA-Based Testing to Move Beyond Research Laboratories III-3
Key and Emerging Players in US III-3
Genova Diagnostics III-3
InterGenetics III-4
Myriad Genetics, Inc. III-4
B.Market Analytics III-5
Table 9: US Recent Past, Current & Future Analysis for
Genetic Testing by Segment-Pharmacogenomic Testing, Prenatal
and Newborn Genetic Testing, and Predictive Medicine Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2009 through 2017 (includes corresponding
Graph/Chart) III-5
Table 10: US Historic Review for Genetic Testing by
Segment-Pharmacogenomic Testing, Prenatal and Newborn
Genetic Testing, and Predictive Medicine Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2003 through 2008 (includes corresponding
Graph/Chart) III-6
Table 11: US 15-Year Perspective for Genetic Testing by
Segment-Pharmacogenomic Testing, Prenatal and Newborn
Genetic Testing, and Predictive Medicine Markets for Years
2003, 2011 & 2017 (includes corresponding Graph/Chart) III-7
2. CANADA III-8
A.Market Analysis III-8
Key Player III-8
Luminex Molecular Diagnostics III-8
B.Market Analytics III-8
Table 12: Canadian Recent Past, Current & Future Analysis
for Genetic Testing - Annual Sales Figures in US$ Million
for Years 2009 through 2017 (includes corresponding
Graph/Chart) III-8
Table 13: Canadian Historic Review for Genetic Testing -
Annual Sales Figures with Annual Sales Figures in US$
Million for Years 2003 through 2008 (includes corresponding
Graph/Chart) III-9
3. JAPAN III-10
Market Analysis III-10
Table 14: Japanese Recent Past, Current & Future Analysis
for Genetic Testing - Annual Sales Figures in US$ Million
for Years 2009 through 2017 (includes corresponding
Graph/Chart). III-10
Table 15: Japanese Historic Review for Genetic Testing -
Annual Sales Figures with Annual Sales Figures in US$
Million for Years 2003 through 2008 (includes corresponding
Graph/Chart) III-11
4. EUROPE III-12
A.Market Analysis III-12
A Brief Overview of Legislations/Regulatory Policies in
Select European Countries III-12
Government Encourages Genetic Testing in UK III-12
Italy III-13
Top Prenatal Genetic Tests Conducted in Italy, by Volume (
2004): A Recent Past Perspective III-13
Top Postnatal Genetic Tests Conducted in Italy, by Volume
(2004): A Recent Past Perspective III-13
IMGM Laboratories GmbH (Germany) - Key Player III-14
B.Market Analytics III-14
Table 16: European Recent Past, Current & Future Analysis
for Genetic Testing - Annual Sales Figures in US$ Million
for Years 2009 through 2017 (includes corresponding
Graph/Chart). III-14
Table 17: European Historic Review for Genetic Testing -
Annual Sales Figures with Annual Sales Figures in US$
Million for Years 2003 through 2008 (includes corresponding
Graph/Chart) III-15
5. REST OF WORLD III-16
A.Market Analysis III-16
Asia & Latin America: The Future Market for Genetic Testing III-16
Approval of Experiments on Human Embryos in New Zealand III-16
Singapore Sets Guidelines for Genetic Research and Testing III-16
B.Market Analytics III-17
Table 18: Rest of World Market for Genetic Testing - Recent
Past, Current & Future Analysis with Annual Sales Figures in
US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart) III-17
Table 19: Rest of World Market for Genetic Testing Historic
Review with Annual Sales Figures in US$ Million for Years
2003 through 2008 (includes corresponding Graph/Chart) III-18
IV. COMPETITIVE LANDSCAPE
Total Companies Profiled: 76 (including Divisions/Subsidiaries - 84)
------------------------------------------
Region/Country Players
------------------------------------------
The United States 62
Canada 4
Europe 15
France 1
Germany 3
The United Kingdom 3
Rest of Europe 8
Asia-Pacific (Excluding Japan) 3
------------------------------------------
To order this report:
In Vitro Diagnostic Industry: Global Genetic Testing Industry
Check our Industry Analysis and Insights
CONTACT
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article